Human medicines European public assessment report (EPAR): Triumeq, abacavir,dolutegravir,lamivudine, Date of authorisation: 31/08/2014, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Triumeq, abacavir,dolutegravir,lamivudine, Date of authorisation: 31/08/2014, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Zavicefta, ceftazidime,avibactam, Date of authorisation: 23/06/2016, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Zavicefta, ceftazidime,avibactam, Date of authorisation: 23/06/2016, Revision: 20, Status: Authorised

Assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in non-food-producing animal species - Scientific guideline

Assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in non-food-producing animal species - Scientific guideline

Concept paper for the development of a guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in non-food-producing animal species

Concept paper for the development of a guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in non-food-producing animal species

Classification of a product as intended for a limited market and eligibility for authorisation under Article 23 of Regulation (EU) 2019/6 (Applications for limited markets)

Classification of a product as intended for a limited market and eligibility for authorisation under Article 23 of Regulation (EU) 2019/6 (Applications for limited markets)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.